Funding Opportunity Number: RFA-DK-27-125
Issuing agency: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Application deadline: November 6, 2026 at 5:00 PM local time of the applicant organization under NIH submission policy, unless the controlling NOFO states otherwise.
Funding: The current federal listing reports approximately $1,900,000 in total program funding for 3 expected awards. Award minimum and maximum are not stated in the federal synopsis. Cost sharing is not required.
Purpose: This limited-competition U01 supports a three-year extension of the COPE-AKI clinical trial consortium’s Clinical Centers so the existing study can complete enrollment, participant follow-up, analysis, and dissemination needed to inform care after Stage 2 and 3 acute kidney injury.
Eligibility: This is not a broad competition. Only current recipients under RFA-DK-20-011, specifically eligible institutions tied to the original COPE-AKI participating Clinical Centers as described in the NOFO, may apply. Non-U.S. organizations and non-U.S. components of U.S. organizations are not eligible, and foreign components are not allowed.
Submission controls: Grants.gov lists the current full-announcement file RFA-DK-27-125-Full-Announcement.html, Version 1, posted August 31, 2026. Eligible incumbents must use the controlling Grants.gov package and full announcement for required clinical-trial forms, attachments, budgets, page limits, and continuation requirements.
Atlas assessment: Restricted limited competition. Do not route for broad applicant outreach. Current-cycle support is appropriate only for verified incumbent COPE-AKI Clinical Center recipients.
Atlas score: 91/100 for program relevance; restricted routing.